Welcome to our dedicated page for Imunon SEC filings (Ticker: IMNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Non-viral DNA immunotherapies sound promising鈥攜et Immunon鈥檚 disclosures are packed with molecular biology, trial protocols, and shifting cash-runway projections. If you have ever searched "What does Immunon report in their SEC filings?" or scrambled to locate Immunon insider trading Form 4 transactions before the market opens, you know how challenging this data hunt can be.
Stock Titan solves the problem. Our AI parses every document鈥攚hether it is the Immunon annual report 10-K simplified or an Immunon quarterly earnings report 10-Q filing鈥攁nd serves concise explanations you can act on. Stop scrolling through clinical tables: our platform flags R&D spend shifts, highlights trial milestones buried in an Immunon 8-K material events explained, and even sends alerts for Immunon Form 4 insider transactions real-time. Key features include:
- AI-powered summaries that turn dense science into plain English鈥攑erfect for understanding Immunon SEC documents with AI
- Instant access to Immunon executive stock transactions Form 4 and ownership changes
- Side-by-side financial trend visualizations for rapid Immunon earnings report filing analysis
- Full proxy coverage, so Immunon proxy statement executive compensation details are never missed
- AG真人官方-time feeds direct from EDGAR鈥攗pdates arrive seconds after filing
Whether you鈥檙e modeling cash burn or gauging sentiment shifts after a Phase II readout, our tools keep you ahead. From "Immunon SEC filings explained simply" to granular drill-downs of trial expenditures, Stock Titan delivers the clarity professionals require.
Imunon, Inc. received a Schedule 13G/A reporting that three related reporting persons 鈥� Ayrton Capital LLC, Alto Opportunity Master Fund, SPC (Segregated Master Portfolio B) and individual Waqas Khatri 鈥� each beneficially own 2,000 shares of the issuer's common stock that are issuable on the exercise of certain warrants and conversion of certain convertible notes. The filing states these holdings represent 0.01% each based on 17,541,732 shares outstanding cited in the issuer's registration statement prior to a July 2025 reverse stock split.
The filing notes the warrants are subject to a 9.99% beneficial ownership blocker and includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Reporting persons Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC disclose beneficial ownership in Imunon, Inc. The filing shows each may be deemed to beneficially own 1,067,196 shares of common stock, representing 4.99% of the class. That figure is calculated using the issuer's reported outstanding shares of 20,319,511 plus 1,067,196 shares issuable upon exercise of an Intracoastal warrant.
The report states sole voting and dispositive power are 0 and shared voting and dispositive power are 1,067,196. It also discloses an additional 1,155,028 warrant shares are excluded because the warrant is not currently exercisable pending stockholder approval and includes a blocker limiting exercise above 4.99%. Without that blocker and if currently exercisable, the filing notes each reporting person could be deemed to own 2,222,224 shares.
Imunon, Inc. (IMNN) Form 4: Director Donald P. Braun reported two transactions dated 08/04/2025 following the company鈥檚 1-for-15 reverse split completed 07/25/2025.
- Equity grant in lieu of cash fees: 2,040 common shares acquired at the split-adjusted closing price of $9.20, increasing Braun鈥檚 direct holdings to 3,747 shares.
- New stock option: right to purchase 250 shares at an exercise price of $9.20; 50% vests immediately, 25% after one year, and the remaining 25% after two years, expiring 08/04/2035.
Post-transaction, Braun also holds 250 options in addition to the common shares. The share acquisition represents payment of board fees in stock rather than cash, signalling alignment with shareholder interests, though the dollar value (<鈮� $18.8 k) is modest relative to market capitalization. No sales were disclosed.
FAQ
What is the current stock price of Imunon (IMNN)?
What is the market cap of Imunon (IMNN)?
